Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorAPIQUIAN, Rogelio
dc.contributor.authorCORDOBA, Rodrigo
dc.contributor.authorLOUZA, Mario
dc.date.accessioned2017-11-27T16:42:02Z
dc.date.available2017-11-27T16:42:02Z
dc.date.issued2011
dc.description.abstractBackground: Risperidone long-acting injection (RLAI) has been shown to be efficacious, improve compliance, and increase long-term retention rate on therapy. The aim of this work was to determine the effect of RLAI on clinical outcome and hospitalization rate in patients with schizophrenia or schizoaffective disorder enrolled in the electronic Schizophrenia Treatment Adherence Registry in Latin America. Methods: Data were collected at baseline, retrospectively for the 12 months prior to baseline, and prospectively every three months for 24 months. Hospitalization prior to therapy was assessed by a retrospective chart review. Efficacy and functioning were evaluated using Clinical Global Impression of Illness Severity (CGI-S), Personal and Social Performance (PSP), and Global Assessment of Functioning (GAF) scores. Relapse and treatment were also registered. Results: Patients were recruited in Mexico (n = 53), Brazil (n = 11), and Colombia (n = 15). Sixty-five percent (n = 52) were male, and mean age was 32.9 years. Patients were classified as having schizophrenia (n = 73) or schizoaffective disorder (n = 6). The mean dose of RLAI at six months was 34.1 mg (standard deviation = 10.2 mg). The percentage of hospitalized patients before treatment was 28.2% and 5.1% at six months after initiating RLAI (P < 0.001). Significant changes were registered on CGI-S, GAF, and PSP scores. Conclusions: RLAI was associated with an improvement in clinical symptoms and functioning, and a greater reduction in hospitalization.
dc.description.indexPubMed
dc.description.sponsorshipCONACYT
dc.description.sponsorshipJanssen Cilag Medical Affairs Department in Mexico
dc.description.sponsorshipJanssen
dc.description.sponsorshipAstraZeneca
dc.description.sponsorshipUCLA
dc.identifier.citationNEUROPSYCHIATRIC DISEASE AND TREATMENT, v.7, p.19-26, 2011
dc.identifier.doi10.2147/NDT.S15911
dc.identifier.issn1176-6328
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/24014
dc.language.isoeng
dc.publisherDOVE MEDICAL PRESS LTD
dc.relation.ispartofNeuropsychiatric Disease and Treatment
dc.rightsopenAccess
dc.rights.holderCopyright DOVE MEDICAL PRESS LTD
dc.subjectlong-acting
dc.subjectrisperidone
dc.subjectschizophrenia
dc.subjectschizoaffective disorder
dc.subjectLatin America
dc.subject.otherquality-of-life
dc.subject.otherantipsychotic medication
dc.subject.other1st-episode schizophrenia
dc.subject.otherschizoaffective disorder
dc.subject.othertreatment response
dc.subject.othercost-effectiveness
dc.subject.otherassessment scale
dc.subject.other1st episode
dc.subject.otheropen-label
dc.subject.otherefficacy
dc.subject.wosClinical Neurology
dc.subject.wosPsychiatry
dc.titleClinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryColômbia
hcfmusp.affiliation.countryMéxico
hcfmusp.affiliation.countryisomx
hcfmusp.affiliation.countryisoco
hcfmusp.author.externalAPIQUIAN, Rogelio:Americas Univ, Behav & Dev Sci Div, Mexico City, DF, Mexico
hcfmusp.author.externalCORDOBA, Rodrigo:Nervous Syst Res Ctr CISNE, Bogota, Colombia
hcfmusp.citation.scopus12
hcfmusp.contributor.author-fmusphcMARIO RODRIGUES LOUZA NETO
hcfmusp.description.beginpage19
hcfmusp.description.endpage26
hcfmusp.description.volume7
hcfmusp.origemWOS
hcfmusp.origem.pubmed21326651
hcfmusp.origem.scopus2-s2.0-79951609794
hcfmusp.origem.wosWOS:000294955100002
hcfmusp.publisher.cityALBANY
hcfmusp.publisher.countryNEW ZEALAND
hcfmusp.relation.referenceAnnemans L, 2005, PHARMACOECONOMICS, V23, P1
hcfmusp.relation.referenceRobinson D, 1999, ARCH GEN PSYCHIAT, V56, P241, DOI 10.1001/archpsyc.56.3.241
hcfmusp.relation.referenceTaylor DM, 2009, J CLIN PSYCHIAT, V70, P196
hcfmusp.relation.referenceGilmer TP, 2004, AM J PSYCHIAT, V161, P692, DOI 10.1176/appi.ajp.161.4.692
hcfmusp.relation.referenceWRIGHT EC, 1993, LANCET, V342, P909, DOI 10.1016/0140-6736(93)91951-H
hcfmusp.relation.referenceMoller HJ, 2005, INT CLIN PSYCHOPHARM, V20, P121
hcfmusp.relation.referenceKeefe RSE, 2007, ARCH GEN PSYCHIAT, V64, P633, DOI 10.1001/archpsyc.64.6.633
hcfmusp.relation.referenceLeucht S, 2009, LANCET, V373, P31, DOI [10.1016/S0140-6736(08)61764-X, 10.1016/S01406736(08)61764-X]
hcfmusp.relation.referenceLacro JP, 2002, J CLIN PSYCHIAT, V63, P892
hcfmusp.relation.referenceFleischhacker WW, 2003, J CLIN PSYCHIAT, V64, P1250
hcfmusp.relation.referenceWiersma D, 1998, SCHIZOPHRENIA BULL, V24, P75
hcfmusp.relation.referenceENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766
hcfmusp.relation.referenceAlmond S, 2004, BRIT J PSYCHIAT, V184, P346, DOI 10.1192/bjp.184.4.346
hcfmusp.relation.referenceValenstein M, 2002, MED CARE, V40, P630, DOI 10.1097/01.MLR.0000021003.43524.64
hcfmusp.relation.referenceRosa MA, 2005, REV BRAS PSIQUIATR, V27, P178, DOI 10.1590/S1516-44462005000300005
hcfmusp.relation.referenceGoeree R, 2005, CURR MED RES OPIN, V21, P2017, DOI 10.1185/030079905X75087
hcfmusp.relation.referenceOlivares JM, 2009, EUR PSYCHIAT, V24, P287, DOI 10.1016/j.eurpsy.2008.12.002
hcfmusp.relation.referenceEmsley R, 2008, INT CLIN PSYCHOPHARM, V23, P325, DOI 10.1097/YIC.0b013e32830c2042
hcfmusp.relation.referenceLehman AF, 1998, SCHIZOPHRENIA BULL, V24, P11
hcfmusp.relation.referenceWEIDEN P, 1995, PSYCHIATR SERV, V46, P1049
hcfmusp.relation.referenceLieberman JA, 1996, J CLIN PSYCHIAT, V57, P5
hcfmusp.relation.referenceLINDENMAYER JP, 1994, J CLIN PSYCHOPHARM, V14, P201
hcfmusp.relation.referenceSwartz MS, 2007, AM J PSYCHIAT, V164, P428, DOI 10.1176/appi.ajp.164.3.428
hcfmusp.relation.referenceDAVIS JM, 1994, DRUGS, V47, P741, DOI 10.2165/00003495-199447050-00004
hcfmusp.relation.referenceFleischhacker WW, 2003, J CLIN PSYCHIAT, V64, P10
hcfmusp.relation.referencePeuskens J, 2010, CURR MED RES OPIN, V26, P501, DOI 10.1185/03007990903488670
hcfmusp.relation.referenceMorosini PL, 2000, ACTA PSYCHIAT SCAND, V101, P323, DOI 10.1111/j.1600-0447.2000.tb10933.x
hcfmusp.relation.referenceRobinson DG, 1999, AM J PSYCHIAT, V156, P544
hcfmusp.relation.referenceDolder CR, 2002, AM J PSYCHIAT, V159, P103, DOI 10.1176/appi.ajp.159.1.103
hcfmusp.relation.referenceNasrallah HA, 2005, PSYCHIAT SERV, V56, P273, DOI 10.1176/appi.ps.56.3.273
hcfmusp.relation.referenceEmsley R, 2008, J CLIN PSYCHOPHARM, V28, P210, DOI 10.1097/JCP.0b013e318167269d
hcfmusp.relation.referenceBeasley CM, 1996, NEUROPSYCHOPHARMACOL, V14, P111, DOI 10.1016/0893-133X(95)00069-P
hcfmusp.relation.referenceKane JM, 2003, AM J PSYCHIAT, V160, P1125, DOI 10.1176/appi.ajp.160.6.1125
hcfmusp.relation.referenceMoore A, 2000, BRIT J CLIN PSYCHOL, V39, P287, DOI 10.1348/014466500163293
hcfmusp.relation.referenceBarkic J, 2003, COLLEGIUM ANTROPOL, V27, P111
hcfmusp.relation.referenceBEBBINGTON PE, 1995, INT CLIN PSYCHOPHARM, V9, P41, DOI 10.1097/00004850-199501005-00008
hcfmusp.relation.referenceBLACKWELL B, 1976, BRIT J PSYCHIAT, V129, P513, DOI 10.1192/bjp.129.6.513
hcfmusp.relation.referenceBuckley PF, 2004, SCHIZOPHR RES, V66, P143, DOI 10.1016/j.schres.2003.06.001
hcfmusp.relation.referenceChue Pierre, 2007, Neuropsychiatr Dis Treat, V3, P13, DOI 10.2147/nedt.2007.3.1.13
hcfmusp.relation.referenceColonna L, 2000, INT CLIN PSYCHOPHARM, V15, P13, DOI 10.1097/00004850-200015010-00002
hcfmusp.relation.referenceEdwards NC, 2005, PHARMACOECONOMICS, V23, P75
hcfmusp.relation.referenceFleischhacker WW, 2005, BRIT J PSYCHIAT, V187, P131, DOI 10.1192/bjp.187.2.131
hcfmusp.relation.referenceHaro JM, 2003, ACTA PSYCHIAT SCAN S, V416, P16
hcfmusp.relation.referenceLambert Tim, 2003, J Psychiatr Pract, V9, P252, DOI 10.1097/00131746-200305000-00011
hcfmusp.relation.referenceLIEBERMAN JA, 1992, SCHIZOPHRENIA BULL, V18, P351
hcfmusp.relation.referenceLindenmayer Jean-Pierre, 2006, J Psychiatr Pract, V12, P55, DOI 10.1097/00131746-200601000-00009
hcfmusp.relation.referenceLindenmayer JP, 2004, J CLIN PSYCHIAT, V65, P1084
hcfmusp.relation.referenceMarcus SC, 2008, SCHIZOPHRENIA BULL, V34, P173, DOI 10.1093/schbul/sbm061
hcfmusp.relation.referenceMarder SR, 1998, J CLIN PSYCHIAT, V59, P21
hcfmusp.relation.referenceMarinis T De, 2007, Pharmacopsychiatry, V40, P257, DOI 10.1055/s-2007-992140
hcfmusp.relation.referenceMartin SD, 2003, CURR MED RES OPIN, V19, P298, DOI 10.1185/030079903125001893
hcfmusp.relation.referenceMasand Prakash S, 2006, Curr Clin Pharmacol, V1, P47, DOI 10.2174/157488406775268255
hcfmusp.relation.referenceMasand Prakash S, 2009, Prim Care Companion J Clin Psychiatry, V11, P147, DOI 10.4088/PCC.08r00612
hcfmusp.relation.referenceNasrallah HA, 2004, J CLIN PSYCHIAT, V65, P531
hcfmusp.relation.referenceParellada E, 2005, J PSYCHOPHARMACOL, V19, P5, DOI 10.1177/0269881105056513
hcfmusp.relation.referencePatel MX, 2008, J CLIN PSYCHIAT, V69, P1548
hcfmusp.relation.referencePereira S, 1997, ACTA PSYCHIAT SCAND, V95, P464, DOI 10.1111/j.1600-0447.1997.tb10133.x
hcfmusp.relation.referencePeuskens J, 2002, EUR NEUROPSYCHOPHARM, V12, P305, DOI 10.1016/S0924-977X(02)00031-7
hcfmusp.relation.referenceREMINGTON GJ, 1995, CAN J PSYCHIAT, V40, pS5
hcfmusp.relation.referenceSchmauss M, 2007, INT CLIN PSYCHOPHARM, V22, P85, DOI 10.1097/YIC.0b013e3280119ddb
hcfmusp.relation.referenceSHEPHERD M, 1989, PSYCHOL MED, P1
hcfmusp.relation.referenceTurner M, 2004, INT CLIN PSYCHOPHARM, V19, P241, DOI 10.1097/01.yic.0000133500.92025.20
hcfmusp.relation.referenceVehof J, 2008, J CLIN PSYCHOPHARM, V28, P625, DOI 10.1097/JCP.0b013e31818a6d10
hcfmusp.relation.referenceWeiden PJ, 2007, J CLIN PSYCHIAT, V68, P12
hcfmusp.scopus.lastupdate2024-04-12
relation.isAuthorOfPublication76318d15-1d2e-4fde-8220-bcd4d3e3bf64
relation.isAuthorOfPublication.latestForDiscovery76318d15-1d2e-4fde-8220-bcd4d3e3bf64
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_APIQUIAN_Clinical_outcomes_of_longacting_injectable_risperidone_in_patients_2011.PDF
Tamanho:
349 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/IPq